Treatment of older adults with acute promyelocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 3, 2003, Pages 495-501

  Fenaux, Pierre ^a   Chevret, Sylvie ^b   de Botton, Stéphane ^c  

^a UNIVERSITÉ PARIS 13   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute promyelocytic leukaemia; Elderly patients

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LIVER TOXICITY; LONG QT SYNDROME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; TREATMENT OUTCOME; CHEMOTHERAPY; EXPERIMENTAL MODEL; NONHUMAN; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; SURVIVAL;

EID: 0041828184     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(03)00044-6     Document Type: Article

References (24)

1. Fenaux P, Chomienne C & Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Seminars in Hematology 2001; 38: 13-25.
2. De Botton S, Coiteux V & Chevret S. Outcome of childhood acute promyelocytic leukemia (APL) with ATRA and chemotherapy: results on 31 cases. Journal of Clinical Oncology 2003;. in press.
3. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
4. Kanamaru A, Takemoto Y, Tanimoto M et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202-1206.
5. Tallman MS, Andersenn JW, Schiffer CA et al. All trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997; 337: 1021-1028.
6. Warrell RP, Maslak P, Eardley A et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 926-933.
7. Sanz MA, Lo Coco F, Martin G et al. Definition of relapse risk and rôle of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
8. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192- 1200.
9. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all-trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-2718.
10. Cunningham I, Gee T & Reich L. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1999; 73: 1116- 1122.
11. Head D, Kopecky KJ, Willman CL et al. Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG) trial. Leukemia 1994; 8(supplement): S38-S41.
12. Fenaux P, Pollet JP, Vandenbossche L et al. Treatment of acute promyelocytic leukemia: a report on 70 cases. Leukemia and Lymphoma 1991; 4: 249-256.
13. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131-4143.
14. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000; 14: 1006-1013.
15. Soignet SL, Frankel SR, Douer D et al. United States multicenter study or arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology 2001; 18: 3852-3860.
16. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
17. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in II newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324.
18. 3: an experience of 120 patients at a single institution. International Journal of Hematology 1999; 70: 248-260.
19. Sanz MA, Martinez JA, Barragan E et al. All-trans retinoic acid and low-dose chemotherapy for acute promyelocytic leukaemia. British Journal of Haematology 2000; 109: 896-897.
20. Estey E, Thall PF, Pierce S et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. Journal of Clinical Oncology 1997; 15: 3021-3022.
21. Avvisati G, Petti MC, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized sutdy LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100: 3141-3146.
22. Latagliata R, Avvisati G, Lo-Coco F et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Annals of Oncology 1997; 8: 1273-1275.
23. Lu DP, Qiu JY, Jiang B et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136-3143.
24. Jing Y, Wang L, Xia L et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269.